Dimitrios Krikelis
Overview
Explore the profile of Dimitrios Krikelis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tampaki E, Tampakis A, Alifieris C, Krikelis D, Pazaiti A, Kontos M, et al.
Clin Drug Investig
. 2018 May;
38(7):639-648.
PMID: 29744672
Background: In the era of personalized therapy, targeted treatment in specific patient populations is mandated. Objective: We evaluated the efficacy and safety of neoadjuvant treatment on locally advanced breast cancer...
2.
Krikelis D, Kotoula V, Bobos M, Fountzilas E, Markou K, Karasmanis I, et al.
Anticancer Res
. 2014 Nov;
34(11):6495-503.
PMID: 25368251
Background: There exist substantial evidence that laryngeal cancer represents a unique entity among squamous head and neck carcinomas. Materials And Methods: Tumors from 289 patients with squamous cell laryngeal cancer...
3.
Krikelis D, Skoura E, Kotoula V, Rondogianni P, Pianou N, Samartzis A, et al.
Anticancer Res
. 2014 Apr;
34(5):2571-9.
PMID: 24778079
Background: Although Kirsten rat sarcoma (KRAS) gene mutational testing is essential for the optimal design of therapeutic strategies for colorectal cancer, it is not always feasible or reliable. In this...
4.
Psyrri A, Kotoula V, Fountzilas E, Alexopoulou Z, Bobos M, Televantou D, et al.
Oral Oncol
. 2014 Jan;
50(4):298-305.
PMID: 24461629
Objectives: We sought to determine the prognostic significance of the Wnt signaling pathway in operable squamous cell carcinoma of the larynx. Materials And Methods: In an annotated cohort of 289...
5.
Kamposioras K, Konstantara A, Kotoula V, Lakis S, Kouvatseas G, Akriviadis E, et al.
Anticancer Res
. 2013 Oct;
33(10):4573-84.
PMID: 24123033
Background: The wingless-type MMTV integration site family of proteins (WNT) pathway is highly involved in colorectal cancer development. The aim of this study was to explore the prognostic significance and...
6.
Pentheroudakis G, Pavlidis N, Fountzilas G, Krikelis D, Goussia A, Stoyianni A, et al.
Mol Cancer
. 2013 Jun;
12:57.
PMID: 23758919
Background: Cancer of unknown or uncertain primary is a major diagnostic and clinical challenge, since identifying the tissue-of-origin of metastases is crucial for selecting optimal treatment. MicroRNAs are a family...
7.
Krikelis D, Bobos M, Karayannopoulou G, Resiga L, Chrysafi S, Samantas E, et al.
BMC Clin Pathol
. 2013 Jan;
13:1.
PMID: 23360534
Unlabelled: Background: Since scarce data exist on the pathogenesis of nasopharyngeal carcinoma in Caucasian patients, we attempted to elucidate the responsible molecular pathways in this patient population. Methods: Formalin-fixed paraffin-embedded...
8.
Pentheroudakis G, Spector Y, Krikelis D, Kotoula V, Meiri E, Malamou-Mitsi V, et al.
Clin Exp Metastasis
. 2012 Nov;
30(4):431-9.
PMID: 23124598
No data exist on biologic differences between Cancer of unknown primary (CUP) and metastatic solid tumors of known primary site. We assigned a primary tissue of origin in 40 favorable...
9.
Kotoula V, Krikelis D, Karavasilis V, Koletsa T, Eleftheraki A, Televantou D, et al.
BMC Cancer
. 2012 Aug;
12:342.
PMID: 22866924
Background: BRCA1 (B), ERCC1 (E), RRM1 (R) and TYMS (T) mRNA expression has been extensively studied with respect to NSCLC patient outcome upon various chemotherapy agents. However, these markers have...
10.
Trafalis D, Alifieris C, Krikelis D, Tzogkas N, Stathopoulos G, Athanassiou A, et al.
Int J Clin Pharmacol Ther
. 2012 May;
50(7):490-9.
PMID: 22578202
Background: Malignant pleural mesothelioma (MPM) is an aggressive disease with poor or modest responses to chemotherapy and dismal prognosis. In most of the cases the scope of the treatment is...